Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1348 • ACR Convergence 2021
Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 Mg Once Daily: Pooled Analysis of Two Phase 3 Studies
Daniel Aletaha¹, Philip Mease², Ralph Lippe³, Frank Behrens⁴, Derek Haaland⁵, Penélope Palominos⁶, Apinya Lertratanakul⁷, Michael Lane⁸, Kevin Douglas⁷, Peter Nash⁹ and Arthur Kavanaugh¹⁰, ¹Medical University Vienna, Vienna, Austria, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁴Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁵McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁶Division of Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc., North Chicago, ⁹Griffith University, Brisbane, Australia, ¹⁰Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Upadacitinib (UPA) 15 mg once daily (QD) has demonstrated efficacy and safety in patients with psoriatic arthritis (PsA) for up to 56 weeks in…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
Abstract Number: 0200 • ACR Convergence 2021
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Marloes Verstappen, Xanthe Matthijssen and Annette H.M van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…
Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Marloes Verstappen¹, Hanna van Steenbergen², Pascal de Jong³ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden Univeristy Medical Center, Leiden, Netherlands, ³Erasmus MC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
Abstract Number: 0963 • ACR Convergence 2021
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
Gordon Lam¹, Andrew Laster², Sarah McCarter², Heather Gladue³, Ahmad Kashif², Erin Siceloff², Victoria Lackey³, Cheryl Robertson³, Ashley Toci² and Leonard Calabrese⁴, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in…
Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Adrian Ciurea¹, Tim Killeen², Raphael Micheroli¹, Norina N Gassman², Hyejin Jo³, Kenneth Kwok⁴, Elizabeth Kudlacz⁴, Oliver Distler¹, Caroline Ospelt⁵ and Mojca Frank-Bertoncelj¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ²Pfizer AG, Zurich, Switzerland, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 0206 • ACR Convergence 2021
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Alba Herrero-Morant¹, Adrián Margarida-de Castro¹, Raquel Pérez-Barquín², Jon Zubiaur-Zamacola¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction…
Abstract Number: 0809 • ACR Convergence 2021
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
Johanna Maria Maassen¹, Sytske Anne Bergstra¹, PDM de Buck², Maikel van Oosterhout³, Cornelia F. Allaart¹ and Tom WJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Haaglanden medical center, The Hague, Netherlands, ³Groene Hart Hospital, Gouda, Netherlands
Background/Purpose: There are many definitions of flare in rheumatoid arthritis (RA). Loss of low disease activity is associated with clinically relevant deterioration. Patients in DAS…
Abstract Number: 0974 • ACR Convergence 2021
Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
Katelyn Baggett¹, Timothy Brandon¹, Rui Xiao², Zachary Valenzuela¹, Lisa Buckley³ and Pamela Weiss¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Vanderbilt Children's Hospital, Nashville, TN
Background/Purpose: Tumor necrosis factor inhibiting (TNFi) therapies are associated with new-onset psoriasis in children with inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA). We…
Abstract Number: 1352 • ACR Convergence 2021
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Atul Deodhar¹, Miroslawa Nowak², June Ye², Tom Lehman², Lan Wei², Subhashis Banerjee² and Philip Mease³, ¹Oregon Health & Science University, Portland, OR, ²Bristol Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA presents with heterogeneous clinical manifestations including joint pain, enthesitis, dactylitis, and skin and nail lesions. Treatment guidelines recommend that PsA patients (pts) who…
Abstract Number: 1693 • ACR Convergence 2021
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Christof Specker¹, Martin Aringer², Gerd Burmester³, Marvin A. Peters⁴, Michael W. Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, ⁶Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Universitätsklinikum Würzburg, Wuerzburg, Germany, ⁹Rheumatology Practice, Osnabrueck, Germany
Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].